Anna Langenbruch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Langenbruch has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Augustin
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP) Universitätsklinikum Hamburg‐Eppendorf (UKE) Hamburg Deutschland
17 shared publications M. Augustin
Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Deutschland
4 shared publications- Natalia Kirsten
CeDeF - Dermatologische Forschung und Ambulanzen, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
4 shared publications M.A. Radtke
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
3 shared publicationsMatthias Augustin
3 shared publications- Nicole Mohr
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
3 shared publications
Latest Publications
- 8 December 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1620-1631
Versorgung von Patienten mit atopischer Dermatitis durch Hausärzte – eine bundesweite Erhebung in Deutschland
Zusammenfassung: Hintergrund und Zielsetzung: Epidemiologische Studien zur dermatologischen Versorgung von Patienten mit atopischer Dermatitis (AD) in Deutschland zeigen innerhalb von 10 Jahren keine Verbesserung. Neben Dermatologen sind vor allem auch Hausärzte (GP) an der Behandlung von Patienten mit AD beteiligt. In dieser Studie wurde die Versorgungssituation erwachsener Patienten, die wegen AD in hausärztlicher Behandlung sind, analysiert.Patienten und Methodik: Die Querschnittserhebung „PsoADA‐AD“ wurde von 2019 bis 2021 bundesweit in hausärztlichen Praxen durchgeführt. Die Ergebnisse wurden mit Daten aus der dermatologischen Versorgung (AtopicHealth2, 2017–2019) verglichen.Ergebnisse: Von den 150 Patienten (mittleres Alter: 40 Jahre, 62,2% weiblich) wurden 39,2% zusätzlich von Dermatologen (GP+D) behandelt. Unter diesen hatten 20,7% eine schwere AD, während dies unter den nur hausärztlich behandelten Patienten (GP only) auf 5,7% zutraf (p < 0,01, AtopicHealth2: 27,6%). Erhebliche Einschränkungen in ihrer Lebensqualität berichteten 31,0% (GP+D) vs. 3,4% (GP only) (p < 0,001, AtopicHealth2: 31,6%). Die meisten Patienten erhielten topische Medikamente, hauptsächlich Glukokortikosteroide. Calcineurininhibitoren wurden aktuell von 2,7% (PsoADA‐AD gesamt) verwendet. Bereits an einer Neurodermitisschulung teilgenommen zu haben, gaben 5,7% (PsoADA‐AD gesamt) an.Schlussfolgerungen: Ein erheblicher Teil der Patienten mit AD in der hausärztlichen Versorgung zeigt eine schlechte Erkrankungskontrolle, wie es auch in der dermatologischen Versorgung beobachtet wurde. Ein Grund könnte der fehlende Einsatz moderner Systemtherapeutika sein.
- 8 December 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1620-1631
Versorgung von Patienten mit atopischer Dermatitis durch Hausärzte – eine bundesweite Erhebung in Deutschland
Zusammenfassung: Hintergrund und Zielsetzung: Epidemiologische Studien zur dermatologischen Versorgung von Patienten mit atopischer Dermatitis (AD) in Deutschland zeigen innerhalb von 10 Jahren keine Verbesserung. Neben Dermatologen sind vor allem auch Hausärzte (GP) an der Behandlung von Patienten mit AD beteiligt. In dieser Studie wurde die Versorgungssituation erwachsener Patienten, die wegen AD in hausärztlicher Behandlung sind, analysiert.Patienten und Methodik: Die Querschnittserhebung „PsoADA‐AD“ wurde von 2019 bis 2021 bundesweit in hausärztlichen Praxen durchgeführt. Die Ergebnisse wurden mit Daten aus der dermatologischen Versorgung (AtopicHealth2, 2017–2019) verglichen.Ergebnisse: Von den 150 Patienten (mittleres Alter: 40 Jahre, 62,2% weiblich) wurden 39,2% zusätzlich von Dermatologen (GP+D) behandelt. Unter diesen hatten 20,7% eine schwere AD, während dies unter den nur hausärztlich behandelten Patienten (GP only) auf 5,7% zutraf (p < 0,01, AtopicHealth2: 27,6%). Erhebliche Einschränkungen in ihrer Lebensqualität berichteten 31,0% (GP+D) vs. 3,4% (GP only) (p < 0,001, AtopicHealth2: 31,6%). Die meisten Patienten erhielten topische Medikamente, hauptsächlich Glukokortikosteroide. Calcineurininhibitoren wurden aktuell von 2,7% (PsoADA‐AD gesamt) verwendet. Bereits an einer Neurodermitisschulung teilgenommen zu haben, gaben 5,7% (PsoADA‐AD gesamt) an.Schlussfolgerungen: Ein erheblicher Teil der Patienten mit AD in der hausärztlichen Versorgung zeigt eine schlechte Erkrankungskontrolle, wie es auch in der dermatologischen Versorgung beobachtet wurde. Ein Grund könnte der fehlende Einsatz moderner Systemtherapeutika sein.
- Open Access
- 3 September 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1620-1629
Healthcare of patients with atopic dermatitis by general practitioners – a nationwide survey in Germany
Summary: Background and Objectives: Epidemiological studies on the health care of patients with atopic dermatitis (AD) in dermatological treatment in Germany indicate no improvements within 10 years. In addition to dermatologists, general practitioners (GPs) are particularly involved in AD treatment. This study analyzed the health care situation of adult patients with AD by GPs.Patients and Methods: The cross‐sectional questionnaire survey “PsoADA” was conducted from 2019 to 2021 in general practices throughout Germany and the results were compared with previous data from dermatology care (AtopicHealth2, 2017–19).Results: Among 150 patients (mean age: 40 years, 62.2% female), 39.2% received additional treatment by a dermatologist (GP+D). 20.7% of GP+D and 5.7% of patients in GP treatment only (GP only) had severe AD (p < 0.01, AtopicHealth2: 27.6%). Major limitations in quality of life were reported by 31.0% (GP+D) versus 3.4% (GP only) (p < 0.001, AtopicHealth2: 31.6%). Most patients received topicals, mainly glucocorticosteroids. Calcineurin inhibitors were currently administered by 2.7% (PsoADA total). Patient education was reported by 5.7% (PsoADA total).Conclusions: A considerable proportion of patients with AD in GP care shows poor outcomes, as has been observed in dermatological care – possibly due to the lack of use of modern systemic therapy.
- 3 September 2024
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 22 (12) , 1620-1629
Open AccessHealthcare of patients with atopic dermatitis by general practitioners – a nationwide survey in Germany
Summary: Background and Objectives: Epidemiological studies on the health care of patients with atopic dermatitis (AD) in dermatological treatment in Germany indicate no improvements within 10 years. In addition to dermatologists, general practitioners (GPs) are particularly involved in AD treatment. This study analyzed the health care situation of adult patients with AD by GPs.Patients and Methods: The cross‐sectional questionnaire survey “PsoADA” was conducted from 2019 to 2021 in general practices throughout Germany and the results were compared with previous data from dermatology care (AtopicHealth2, 2017–19).Results: Among 150 patients (mean age: 40 years, 62.2% female), 39.2% received additional treatment by a dermatologist (GP+D). 20.7% of GP+D and 5.7% of patients in GP treatment only (GP only) had severe AD (p < 0.01, AtopicHealth2: 27.6%). Major limitations in quality of life were reported by 31.0% (GP+D) versus 3.4% (GP only) (p < 0.001, AtopicHealth2: 31.6%). Most patients received topicals, mainly glucocorticosteroids. Calcineurin inhibitors were currently administered by 2.7% (PsoADA total). Patient education was reported by 5.7% (PsoADA total).Conclusions: A considerable proportion of patients with AD in GP care shows poor outcomes, as has been observed in dermatological care – possibly due to the lack of use of modern systemic therapy.
- 27 April 2024
- Published by S. Karger AG in Dermatology
- Vol. 240 (4) , 653-658
Dermatology Life Quality Index in Patients with Atopic Dermatitis: Are “Not Relevant” Responses Relevant?
Introduction: According to the DLQI user manual, the patients’ answers “not relevant” (NR) and “not at all” (affected in this aspect of life by the skin problem) are treated equally and interpreted as no impairment in health-related quality of life (HRQoL). The aim of this study was to gain more insights about “NR” responders with atopic dermatitis (AD). Methods: A total of 3,353 patients with AD, recruited from dermatological offices and a patient organisation, were surveyed in three cross-sectional studies. Disease severity (SCORAD) and subjective health status (EQ VAS) were compared for each DLQI item between patients who answered “NR” and all others according to their response category. Different DLQI scoring versions were analysed. Results: Those who stated “NR” in terms of HRQoL limitations in the DLQI domains sports, work/study, and sexual relationships were comparable in AD severity and health status to those who felt that their HRQoL was “a little affected.” Some alternative DLQI scoring versions correlated slightly higher with the SCORAD and EQ VAS than the original DLQI. Conclusion: Patients with AD who rate certain life domains as “NR” in the DLQI are most similar in their disease burden to patients who feel a little affected in these areas of life. This suggests that some HRQoL limitations are underestimated by the traditional DLQI scoring. However, different scoring solutions did not lead to substantially higher correlations with other disease burden criteria compared to the original. Therefore, the gain in validity by alternative versions is small.
- 27 April 2024
- Published by S. Karger AG in Dermatology
- Vol. 240 (4) , 653-658
Dermatology Life Quality Index in Patients with Atopic Dermatitis: Are “Not Relevant” Responses Relevant?
Introduction: According to the DLQI user manual, the patients’ answers “not relevant” (NR) and “not at all” (affected in this aspect of life by the skin problem) are treated equally and interpreted as no impairment in health-related quality of life (HRQoL). The aim of this study was to gain more insights about “NR” responders with atopic dermatitis (AD). Methods: A total of 3,353 patients with AD, recruited from dermatological offices and a patient organisation, were surveyed in three cross-sectional studies. Disease severity (SCORAD) and subjective health status (EQ VAS) were compared for each DLQI item between patients who answered “NR” and all others according to their response category. Different DLQI scoring versions were analysed. Results: Those who stated “NR” in terms of HRQoL limitations in the DLQI domains sports, work/study, and sexual relationships were comparable in AD severity and health status to those who felt that their HRQoL was “a little affected.” Some alternative DLQI scoring versions correlated slightly higher with the SCORAD and EQ VAS than the original DLQI. Conclusion: Patients with AD who rate certain life domains as “NR” in the DLQI are most similar in their disease burden to patients who feel a little affected in these areas of life. This suggests that some HRQoL limitations are underestimated by the traditional DLQI scoring. However, different scoring solutions did not lead to substantially higher correlations with other disease burden criteria compared to the original. Therefore, the gain in validity by alternative versions is small.
- Open Access
- 31 August 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv6532
PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
Enhanced treatment options for psoriasis and growing use of guidelines increased the potential to better quality of psoriasis care in Europe. The aim of the PsoBarrier EU study is to compare the quality and processes of psoriasis care in four European countries with different healthcare systems, based on validated quality indicators. This cross-sectional survey was conducted in dermatology centres in Denmark, Germany, Poland and Spain on 1,304 patients, using standardized patient and physician questionnaires. Measured by quality of psoriasis care indicators, patients in Poland had the most critical outcomes, such as the highest disease severity (Psoriasis Area and Severity Index; PASI) and lowest health-related quality of life (Dermatology Life Quality Index; DLQI). This indicates differences in psoriasis care, with Polish participants experiencing more severe psoriasis and its consequences. Differences in the healthcare systems, which create barriers to accessing treatments, could explain variations in quality of care.
- 31 August 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv6532
Open AccessPsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries
Enhanced treatment options for psoriasis and growing use of guidelines increased the potential to better quality of psoriasis care in Europe. The aim of the PsoBarrier EU study is to compare the quality and processes of psoriasis care in four European countries with different healthcare systems, based on validated quality indicators. This cross-sectional survey was conducted in dermatology centres in Denmark, Germany, Poland and Spain on 1,304 patients, using standardized patient and physician questionnaires. Measured by quality of psoriasis care indicators, patients in Poland had the most critical outcomes, such as the highest disease severity (Psoriasis Area and Severity Index; PASI) and lowest health-related quality of life (Dermatology Life Quality Index; DLQI). This indicates differences in psoriasis care, with Polish participants experiencing more severe psoriasis and its consequences. Differences in the healthcare systems, which create barriers to accessing treatments, could explain variations in quality of care.
- Open Access
- 1 June 2023
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 17, 1335-1345
Development of a Specific Variant of Patient Benefit Index (PBI) Assessing Patient Needs, Goals and Benefits in Rosacea Treatment
Introduction: Evaluation of patient-reported outcomes including health-related quality of life (HRQoL) and perceived benefits from treatment has become a fundamental component of medical decision-making. Standardized evaluation of treatment benefits in rosacea based on patient preferences is still lacking. Objective: Development and validation of an instrument for recording patient-defined benefits in rosacea therapy based on the Patient Benefit Index (PBI) methodology. Patients and Methods: In an open survey of n = 50 patients, potential benefits of therapy from the patient’s perspective were examined. The generated item pool was combined with pre-existing PBI items for other skin conditions and reviewed by an expert panel of dermatologists, psychologists and patients. Items were condensed to n = 25 and converted into a Likert-scaled questionnaire. The validity and feasibility of the resulting Patient Benefit Index for rosacea (PBI-RO) were tested on individuals with rosacea recruited from a German rosacea patient organization. Results: N = 446 patients with rosacea completed the PBI-RO. The internal consistencies measured by Cronbach’s alpha were high (Patient Needs Questionnaire [PNQ] 0.94). Mean PBI-RO was 1.9 ± 1.2 (scale from 0 = no benefit to 4 = maximum benefit), 23.5% of the patients experienced a PBI-RO < 1 (no clinically relevant benefit). The PBI-RO correlated with HRQoL, health state, current extent of rosacea lesions and treatment satisfaction. The highest correlation was found between PBI-RO and satisfaction with previous treatment (r = − 0.59, p < 0.001); correlation with the extent of rosacea lesions was low (r = 0.16, p < 0.001). Conclusion: The PBI-RO shows satisfying internal consistency and construct validity. It offers the option of a patient-weighted evaluation of the therapeutic benefit of rosacea therapy and may add to more stringent goal orientation in therapy.
- 1 June 2023
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 17, 1335-1345
Open AccessDevelopment of a Specific Variant of Patient Benefit Index (PBI) Assessing Patient Needs, Goals and Benefits in Rosacea Treatment
Introduction: Evaluation of patient-reported outcomes including health-related quality of life (HRQoL) and perceived benefits from treatment has become a fundamental component of medical decision-making. Standardized evaluation of treatment benefits in rosacea based on patient preferences is still lacking. Objective: Development and validation of an instrument for recording patient-defined benefits in rosacea therapy based on the Patient Benefit Index (PBI) methodology. Patients and Methods: In an open survey of n = 50 patients, potential benefits of therapy from the patient’s perspective were examined. The generated item pool was combined with pre-existing PBI items for other skin conditions and reviewed by an expert panel of dermatologists, psychologists and patients. Items were condensed to n = 25 and converted into a Likert-scaled questionnaire. The validity and feasibility of the resulting Patient Benefit Index for rosacea (PBI-RO) were tested on individuals with rosacea recruited from a German rosacea patient organization. Results: N = 446 patients with rosacea completed the PBI-RO. The internal consistencies measured by Cronbach’s alpha were high (Patient Needs Questionnaire [PNQ] 0.94). Mean PBI-RO was 1.9 ± 1.2 (scale from 0 = no benefit to 4 = maximum benefit), 23.5% of the patients experienced a PBI-RO < 1 (no clinically relevant benefit). The PBI-RO correlated with HRQoL, health state, current extent of rosacea lesions and treatment satisfaction. The highest correlation was found between PBI-RO and satisfaction with previous treatment (r = − 0.59, p < 0.001); correlation with the extent of rosacea lesions was low (r = 0.16, p < 0.001). Conclusion: The PBI-RO shows satisfying internal consistency and construct validity. It offers the option of a patient-weighted evaluation of the therapeutic benefit of rosacea therapy and may add to more stringent goal orientation in therapy.
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (4) , 588-589
Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form
- 1 October 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (4) , 588-589
Open AccessMeasuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form
- Open Access
- 18 May 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (9) , 1450-1455
Determinants of costs and benefits in atopic dermatitis routine care in Germany
Background and objectives: The economic burden of atopic dermatitis (AD) is of particular interest. The present study aims to analyse the association of disease‐related characteristics, annual costs and treatment benefits in AD.Methods: Between August 2017 and June 2019, a cross‐sectional observational study in patients with AD was conducted in Germany. Cost‐of‐illness data were assessed from the societal perspective. Disease characteristics included severity, time since diagnosis and therapy, as well as atopic comorbidity and the implementation of prevention measures. Subgroup analyses of the total costs were conducted for these characteristics. A linear regression model was applied to analyse the impact of disease characteristics on the costs. Furthermore, associations of biologic treatment with outcome parameters were analysed.Results: A total of 1291 patients from 111 centres were included in the analyses. The total costs amounted on average to € 3660 ± € 6428 per patient and year. Higher costs were shown in various patient groups, for example, in patients using biologics (€ 20 983 vs. € 2470). In a regression analysis, gender, education and the number of implemented prevention measures were identified as significant predictors of costs. Patients treated with biologics showed consistently better outcome parameters and were more often satisfied with their treatment.Conclusions: Gender, education and implemented prevention measures are significant cost determinants in AD. The results confirm that treatment with biologics is the main cost driver in AD. However, incremental patient‐relevant benefits of high‐priced therapy are reflected by the significantly better clinical outcomes in the group treated with biologics.
- 18 May 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (9) , 1450-1455
Open AccessDeterminants of costs and benefits in atopic dermatitis routine care in Germany
Background and objectives: The economic burden of atopic dermatitis (AD) is of particular interest. The present study aims to analyse the association of disease‐related characteristics, annual costs and treatment benefits in AD.Methods: Between August 2017 and June 2019, a cross‐sectional observational study in patients with AD was conducted in Germany. Cost‐of‐illness data were assessed from the societal perspective. Disease characteristics included severity, time since diagnosis and therapy, as well as atopic comorbidity and the implementation of prevention measures. Subgroup analyses of the total costs were conducted for these characteristics. A linear regression model was applied to analyse the impact of disease characteristics on the costs. Furthermore, associations of biologic treatment with outcome parameters were analysed.Results: A total of 1291 patients from 111 centres were included in the analyses. The total costs amounted on average to € 3660 ± € 6428 per patient and year. Higher costs were shown in various patient groups, for example, in patients using biologics (€ 20 983 vs. € 2470). In a regression analysis, gender, education and the number of implemented prevention measures were identified as significant predictors of costs. Patients treated with biologics showed consistently better outcome parameters and were more often satisfied with their treatment.Conclusions: Gender, education and implemented prevention measures are significant cost determinants in AD. The results confirm that treatment with biologics is the main cost driver in AD. However, incremental patient‐relevant benefits of high‐priced therapy are reflected by the significantly better clinical outcomes in the group treated with biologics.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 611-621
Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy
Purpose: Allergic rhinoconjunctivitis (ARC) is one of the most common diseases worldwide. Allergen immunotherapy (AIT) is the only causal treatment available so far. Due to health policy provisions, the assessment of treatment benefit from the patient’s perspective is of high relevance. To date, no instrument for assessing treatment needs and benefits of patients with ARC who receive AIT has been published. The aim of the study was to validate an instrument to assess the patient-relevant treatment benefit of patients with ARC who receive AIT. Methods: We developed the Patient Benefit Index questionnaire for AIT (PBI-AIT), consisting of 33 items. Longitudinal data of patients with ARC were used to test feasibility, reliability and validity. The PBI was compared between the beginning of the study (t1) and the end of the study (t5). Results: N = 279 patients with AIT completed the PBI-AIT at t1, n = 333 at t5; n = 226 at both timepoints. Mean number of missing values per patient was 0.7 in the Patient Needs Questionnaire (PNQ) at t1 and 1.2 in the Patient Benefit Questionnaire (PBQ) at t5. The internal consistencies measured by Cronbach’s alpha were 0.98 (PNQ) and 0.99 (PBQ). The mean PBI of the patients with AIT was significantly lower at t1 and improved at t5. The PBI-AIT correlated with all tested external criteria at t5. The correlation between PBI-AIT and satisfaction with previous treatment (r = − 0.57, p < 0.001) was higher than the correlation between PBI-AIT and current disease severity (r = − 0.26, p < 0.001). Conclusion: The results indicate feasibility, reliability, convergent and discriminant validity as well as sensitivity to change of the PBI-AIT.
- 1 May 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 611-621
Open AccessDevelopment and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy
Purpose: Allergic rhinoconjunctivitis (ARC) is one of the most common diseases worldwide. Allergen immunotherapy (AIT) is the only causal treatment available so far. Due to health policy provisions, the assessment of treatment benefit from the patient’s perspective is of high relevance. To date, no instrument for assessing treatment needs and benefits of patients with ARC who receive AIT has been published. The aim of the study was to validate an instrument to assess the patient-relevant treatment benefit of patients with ARC who receive AIT. Methods: We developed the Patient Benefit Index questionnaire for AIT (PBI-AIT), consisting of 33 items. Longitudinal data of patients with ARC were used to test feasibility, reliability and validity. The PBI was compared between the beginning of the study (t1) and the end of the study (t5). Results: N = 279 patients with AIT completed the PBI-AIT at t1, n = 333 at t5; n = 226 at both timepoints. Mean number of missing values per patient was 0.7 in the Patient Needs Questionnaire (PNQ) at t1 and 1.2 in the Patient Benefit Questionnaire (PBQ) at t5. The internal consistencies measured by Cronbach’s alpha were 0.98 (PNQ) and 0.99 (PBQ). The mean PBI of the patients with AIT was significantly lower at t1 and improved at t5. The PBI-AIT correlated with all tested external criteria at t5. The correlation between PBI-AIT and satisfaction with previous treatment (r = − 0.57, p < 0.001) was higher than the correlation between PBI-AIT and current disease severity (r = − 0.26, p < 0.001). Conclusion: The results indicate feasibility, reliability, convergent and discriminant validity as well as sensitivity to change of the PBI-AIT.
- Open Access
- 20 September 2021
- Published by Springer Nature in Die Dermatologie
- Vol. 72 (12) , 1079-1089
Qualität der dermatologischen Versorgung von Neurodermitis in Deutschland – keine Verbesserung der Indikatoren nach 10 Jahren
Zusammenfassung Hintergrund Mit AtopicHealth1 wurde 2010 die erste nationale Versorgungsstudie zur AD durchgeführt. Damals zeigte etwa ein Drittel der Patienten, die sich in einer Behandlung bei Dermatologen befanden, starke Einschränkungen der Lebensqualität, was auf eine unzureichende Versorgungsqualität hindeutete. Ziel der vorliegenden Studie war die Charakterisierung der aktuellen Versorgung von Patienten mit Neurodermitis in dermatologischer Behandlung im Schweregradvergleich sowie im Vergleich zu 2010 und zu Psoriasis. Methode Die deutschlandweite multizentrische Querschnittstudie „AtopicHealth2“ erfasste klinische Daten, Lebensqualität (DLQI), Therapien, präventives Verhalten und patientendefinierten Behandlungsnutzen (PBI). Patienten mit einer Indikation für Systemtherapie wurden für Subgruppenanalysen als mittelschwer bis schwer, die anderen als leicht betroffen angesehen. Ergebnisse Zwischen 2017 und 2019 wurden 1291 Patienten durch 111 Zentren eingeschlossen, mittleres Alter 41 Jahre, 56,5 % weiblich. Im Vergleich zu 2010 fanden sich keine Verbesserungen hinsichtlich Lebensqualität (jeweils DLQI 8,5), Schweregrad (SCORAD 45,4 vs. 42,3 in 2010) und Therapienutzen (PBI 2,2 vs. 2,4 in 2010). Mittelschwer bis schwer betroffene Patienten zeigten häufiger Lebensqualitätseinbuße (45,4 % vs. 23,6 %) und seltener relevante Therapienutzen (PBI < 1: 21,3 % vs. 13,2 %) als leichter betroffene. Verglichen mit Psoriasis offenbarten die Patienten mit Neurodermitis höhere Lebensqualitätseinschränkungen (DLQI 8,5 vs. 6,1) und einen geringeren Behandlungsnutzen (PBI 2,2 vs. 2,8). Diskussion Im Vergleich zu 2010 zeigt sich keine verbesserte Versorgungsqualität von Neurodermitis in Deutschland. Im Vergleich zur Psoriasis weisen Patienten mit Neurodermitis höhere Belastungen und geringere therapeutische Nutzen auf, was den Bedarf an therapeutischen Innovationen unterstreicht.
- 20 September 2021
- Published by Springer Nature in Die Dermatologie
- Vol. 72 (12) , 1079-1089
Open AccessQualität der dermatologischen Versorgung von Neurodermitis in Deutschland – keine Verbesserung der Indikatoren nach 10 Jahren
Zusammenfassung Hintergrund Mit AtopicHealth1 wurde 2010 die erste nationale Versorgungsstudie zur AD durchgeführt. Damals zeigte etwa ein Drittel der Patienten, die sich in einer Behandlung bei Dermatologen befanden, starke Einschränkungen der Lebensqualität, was auf eine unzureichende Versorgungsqualität hindeutete. Ziel der vorliegenden Studie war die Charakterisierung der aktuellen Versorgung von Patienten mit Neurodermitis in dermatologischer Behandlung im Schweregradvergleich sowie im Vergleich zu 2010 und zu Psoriasis. Methode Die deutschlandweite multizentrische Querschnittstudie „AtopicHealth2“ erfasste klinische Daten, Lebensqualität (DLQI), Therapien, präventives Verhalten und patientendefinierten Behandlungsnutzen (PBI). Patienten mit einer Indikation für Systemtherapie wurden für Subgruppenanalysen als mittelschwer bis schwer, die anderen als leicht betroffen angesehen. Ergebnisse Zwischen 2017 und 2019 wurden 1291 Patienten durch 111 Zentren eingeschlossen, mittleres Alter 41 Jahre, 56,5 % weiblich. Im Vergleich zu 2010 fanden sich keine Verbesserungen hinsichtlich Lebensqualität (jeweils DLQI 8,5), Schweregrad (SCORAD 45,4 vs. 42,3 in 2010) und Therapienutzen (PBI 2,2 vs. 2,4 in 2010). Mittelschwer bis schwer betroffene Patienten zeigten häufiger Lebensqualitätseinbuße (45,4 % vs. 23,6 %) und seltener relevante Therapienutzen (PBI < 1: 21,3 % vs. 13,2 %) als leichter betroffene. Verglichen mit Psoriasis offenbarten die Patienten mit Neurodermitis höhere Lebensqualitätseinschränkungen (DLQI 8,5 vs. 6,1) und einen geringeren Behandlungsnutzen (PBI 2,2 vs. 2,8). Diskussion Im Vergleich zu 2010 zeigt sich keine verbesserte Versorgungsqualität von Neurodermitis in Deutschland. Im Vergleich zur Psoriasis weisen Patienten mit Neurodermitis höhere Belastungen und geringere therapeutische Nutzen auf, was den Bedarf an therapeutischen Innovationen unterstreicht.
- Open Access
- 13 March 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (7) , 1536-1542
Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017
Background: In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor proportion received systemic drugs. Since 2007, a national psoriasis programme has been conducted.Objectives: (1) To analyse the quality of health care for psoriasis in the most recent PsoHealth4 survey 2016/17, (2) to compare health care quality indicators with prior assessments since 2004/05.Materials and methods: The recent cross‐sectional PsoHealth4 survey was conducted 2016/17, and three preceding studies were performed in 2004/05, 2007 and 2013/14, each including at least 1500 patients. The common set of quality indicators included disease severity (PASI and proportion of patients with PASI > 20, indicating high severity), quality of life (DLQI and proportion of patients with DLQI > 10, indicating strong impairments in quality of life), systemic therapy and inpatient treatment of the last five years.Results: Between December 2015 and December 2017, n = 1827 patients from 93 dermatological centres were included in the most recent survey (mean age: 50.8 ± 14.6 years, 45.2% female). 7.3% showed a PASI > 20, compared to 17.8% in 2004/05. 21.4% reported a DLQI > 10, compared to 34.0% in 2004/05. 57.6% of all participants stated to have received a systemic therapy at least once within the last five years, compared to 32.9% in 2004/05. 18.0% received inpatient hospital treatment at least once within the last five years, compared to 26.9% in 2004/05.Conclusion: A remarkable improvement in the health care quality for psoriasis patients in Germany within the past 12 years can be assumed. Major determinants could be the innovation shift which included programmes such as the S3 guideline, a consensus on treatment goals, national health care goals for psoriasis and higher utilisation of innovative drugs.
- 13 March 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (7) , 1536-1542
Open AccessQuality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017
Background: In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor proportion received systemic drugs. Since 2007, a national psoriasis programme has been conducted.Objectives: (1) To analyse the quality of health care for psoriasis in the most recent PsoHealth4 survey 2016/17, (2) to compare health care quality indicators with prior assessments since 2004/05.Materials and methods: The recent cross‐sectional PsoHealth4 survey was conducted 2016/17, and three preceding studies were performed in 2004/05, 2007 and 2013/14, each including at least 1500 patients. The common set of quality indicators included disease severity (PASI and proportion of patients with PASI > 20, indicating high severity), quality of life (DLQI and proportion of patients with DLQI > 10, indicating strong impairments in quality of life), systemic therapy and inpatient treatment of the last five years.Results: Between December 2015 and December 2017, n = 1827 patients from 93 dermatological centres were included in the most recent survey (mean age: 50.8 ± 14.6 years, 45.2% female). 7.3% showed a PASI > 20, compared to 17.8% in 2004/05. 21.4% reported a DLQI > 10, compared to 34.0% in 2004/05. 57.6% of all participants stated to have received a systemic therapy at least once within the last five years, compared to 32.9% in 2004/05. 18.0% received inpatient hospital treatment at least once within the last five years, compared to 26.9% in 2004/05.Conclusion: A remarkable improvement in the health care quality for psoriasis patients in Germany within the past 12 years can be assumed. Major determinants could be the innovation shift which included programmes such as the S3 guideline, a consensus on treatment goals, national health care goals for psoriasis and higher utilisation of innovative drugs.